Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SEL 110

Next Previous
Drug Profile

SEL 110

Alternative Names: ImmTOR; SEL-110; SEL-110.36; SVP Rapamycin; SVP-R

Latest Information Update: 22 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Selecta Biosciences
  • Developer Cartesian Therapeutics; National Cancer Institute (USA)
  • Class Anti-infectives; Anti-inflammatories; Antiepileptic drugs; Antifungals; Antineoplastics; Cardiovascular therapies; Eye disorder therapies; Gene therapies; Lactones; Macrolides; Nootropics; Polyenes; Pyridines; Skin disorder therapies
  • Mechanism of Action Immunosuppressants; Methylmalonyl CoA mutase stimulants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Gout
  • No development reported Immunological disorders; Inborn urea cycle disorders; Mesothelioma; Methylmalonic acidaemia

Most Recent Events

  • 12 Jun 2024 Efficacy and adverse event data from a phase III DISSOLVE I trial in Gout presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
  • 01 Dec 2022 Selecta Biosciences in collaboration with Swedish Orphan Biovitrum completes a phase III DISSOLVE I trial in Gout (Treatment experienced, Combination therapy) (IV, Infusion) in the US (NCT04513366)
  • 28 Jun 2021 No recent reports of development identified for preclinical development in Methylmalonic-acidaemia in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top